Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Erica S. Tsang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2317-2721; OpenAlex author ID A5008869204, A5132866038. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 2, last author 1)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
92
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper, 1 trial · 2024: 1 paper · 2025: 7 papers, 2 trials · 2026: 6 papers

Papers 21

  1. Examination of DNA methylation patterns in pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-10421877/v1↗
  2. Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Co… Co-author DOI 10.3390/curroncol33060337↗
  3. Canadian National Pancreas Conference 2025: Recent Advances in Patient-Centred Management of Pancreatic Cancer. Co-author DOI 10.3390/curroncol33100629↗
  4. Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.04.07.717011↗
  5. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  6. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  7. Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma. First author DOI 10.1007/s12029-024-01149-w↗
  8. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  9. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Last author DOI 10.1038/s41698-025-00888-8↗
  10. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  11. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  12. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  13. Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic… Co-author DOI 10.1200/oa-25-00099↗
  14. Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. Co-author DOI 10.3390/curroncol31100461↗
  15. Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-2260↗
  16. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. First author DOI 10.1038/s41467-022-33718-7↗
  17. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Co-author DOI 10.1158/1078-0432.ccr-20-1042↗
  18. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  19. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Co-author DOI 10.2217/imt-2021-0008↗
  20. Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000500↗
  21. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000625↗

Trials 3

  1. A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment Principal investigator NCT06453486↗
  2. Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer Principal investigator NCT06783140↗
  3. Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial Principal investigator NCT05927298↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 12 shared papers, 2021–2026 · strength 2.11
  2. Grainne Mary O'Kane · 12 shared papers, 2021–2026 · strength 1.99
  3. Faiyaz Notta · 12 shared papers, 2021–2026 · strength 1.99
  4. Jennifer Jane Knox · 11 shared papers, 2021–2026 · strength 1.72
  5. Robert C. Grant · 9 shared papers, 2025–2026 · strength 1.70
  6. Eugenia Flores Figueroa · 5 shared papers, 2025–2026 · strength 1.05
  7. George Zogopoulos · 5 shared papers, 2024–2026 · strength 0.91
  8. Michelle Chan‐Seng‐Yue · 5 shared papers, 2025–2026 · strength 0.90
  9. Daniel John Renouf · 7 shared papers, 2019–2025 · strength 0.89
  10. Eileen Mary O'Reilly · 4 shared papers, 2025–2026 · strength 0.76
  11. David Arthur Tuveson · 4 shared papers, 2025–2026 · strength 0.72
  12. Tuan Anh Hoang · 2 shared papers, 2025 · strength 0.71
  13. Spring Holter · 4 shared papers, 2025–2026 · strength 0.69
  14. Sandra Elisabeth Fischer · 4 shared papers, 2025 · strength 0.65
  15. Raymond Jang · 4 shared papers, 2025 · strength 0.65
  16. Sharlene Gill · 4 shared papers, 2019–2026 · strength 0.61
  17. Yuanchang Fang · 3 shared papers, 2025–2026 · strength 0.57
  18. Barbara T. Grünwald · 3 shared papers, 2025–2026 · strength 0.54
  19. Daniel A. King · 3 shared papers, 2025–2026 · strength 0.53
  20. Andrew J. Aguirre · 3 shared papers, 2025–2026 · strength 0.53
  21. Elizabeth M. Jaffee · 3 shared papers, 2025–2026 · strength 0.53
  22. Brian Matthew Wolpin · 3 shared papers, 2025–2026 · strength 0.53
  23. Kimberly J. Perez · 3 shared papers, 2025–2026 · strength 0.53
  24. Kenneth H. Yu · 3 shared papers, 2025–2026 · strength 0.53
  25. Joanna M. Karasinska · 4 shared papers, 2021–2025 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.